Last reviewed · How we verify

NCT03873974

Performance Evaluation of the DualDur In Vitro Diagnostic System in the Diagnosis of Lyme Borreliosis

Completed Last updated 2 March 2020
What this trial tests

trial testing DualDur dark-field microscopic test in Lyme Borreliosis in 400 participants. Completed in 4 December 2019.

Timeline
2 July 2019
Primary endpoint
25 November 2019
4 December 2019

Quick facts

Lead sponsorLyme Diagnostics Ltd.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment400
Start date2 July 2019
Primary completion25 November 2019
Estimated completion4 December 2019
Sites8 locations across Slovakia, Austria, Germany, Poland, Hungary, Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Lyme Diagnostics Ltd.

Who can join

18 and older, any sex, with Lyme Borreliosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The clinical data from the clinical trial will be used to assess the performance, sensitivity and specificity of the experimental DualDur In Vitro Diagnostic System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lyme Borreliosis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03873974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing